Gopalaswamy R, Shanmugam S, Mondal R, Subbian S. Of tuberculosis and non-tuberculous mycobacterial infections – a comparative analysis of epidemiology, diagnosis and treatment. J Biomed Sci. 2020;27:74.
Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The rise of non-tuberculosis mycobacterial lung disease. Front Immunol. 2020;11:303.
Kim BG, Jhun BW, Kim H, Kwon OJ. Treatment outcomes of Mycobacterium avium complex pulmonary disease according to disease severity. Sci Rep. 2022;12:1970.
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71:905–13.
Taylor JL, Palmer SM. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transpl. 2006;25:985–8.
Huh HJ, Kim SY, Shim HJ, Kim DH, Yoo IY, Kang OK et al. GenoType NTM-DR performance evaluation for identification of mycobacterium avium complex and mycobacterium abscessus and determination of clarithromycin and amikacin resistance. J Clin Microbiol. 2019;57:e00516-19.
Ruth MM, Sangen JJN, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, et al. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother. 2019;74:935–43.
Thiour-Mauprivez C, Martin-Laurent F, Calvayrac C, Barthelmebs L. Effects of herbicide on non-target microorganisms: towards a new class of biomarkers? Sci Total Environ. 2019;684:314–25.
Sohn H, Lee KS, Ko YK, Ryu JW, Woo JC, Koo DW, et al. In vitro and ex vivo activity of new derivatives of acetohydroxyacid synthase inhibitors against Mycobacterium tuberculosis and non-tuberculous mycobacteria. Int J Antimicrob Agents. 2008;31:567–71.
Choi KJ, Yu YG, Hahn HG, Choi JD, Yoon MY. Characterization of acetohydroxyacid synthase from Mycobacterium tuberculosis and the identification of its new inhibitor from the screening of a chemical library. FEBS Lett. 2005;579:4903–10.
Gokhale K, Tilak B. Mechanisms of bacterial acetohydroxyacid synthase (AHAS) and specific inhibitors of Mycobacterium tuberculosis AHAS as potential drug candidates against tuberculosis. Curr Drug Targets. 2015;16:689–99.
Saxena S, Spaink HP, Forn-Cuni G. Drug resistance in nontuberculous mycobacteria: mechanisms and models. Biology (Basel). 2021;10:96.
Song CH, Kim HJ, Lim HJ et al. Novel compound and pharmaceutical composition for treating Mycobacterium tuberculosis ir nontuberculous Mycobacterium infection comprising the same. KR 20230106356. 2023.
Garcia MD, Chua SMH, Low YS, Lee YT, Agnew-Francis K, Wang JG, et al. Commercial AHAS-inhibiting herbicides are promising drug leads for the treatment of human fungal pathogenic infections. Proc Natl Acad Sci USA. 2018;115:E9649–E9658.
Sun Y, Zhang Y et al. Preparation method of diclosulam. CN 106905323. 2017.
Institute CaLS. M62: Performance Standards for Susceptibility Testing of Mycobacteria,Nocardia spp., and Other Aerobic Actinomycetes. CLSI: Wayne, PA, 2018.
Parvekar P, Palaskar J, Metgud S, Maria R, Dutta S. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of silver nanoparticles against Staphylococcus aureus. Biomater Investig Dent. 2020;7:105–9.
Son SH, Lee J, Cho SN, Choi JA, Kim J, Nguyen TD, et al. Herp regulates intracellular survival of Mycobacterium tuberculosisH37Ra in macrophages by regulating reactive oxygen species-mediated autophagy. mBio. 2023;14:e0153523.
Magi G, Marini E, Facinelli B. Antimicrobial activity of essential oils and carvacrol, and synergy of carvacrol and erythromycin, against clinical, erythromycin-resistant Group A Streptococci. Front Microbiol. 2015;6:165.
Bonapace CR, Bosso JA, Friedrich LV, White RL. Comparison of methods of interpretation of checkerboard synergy testing. Diagn Microbiol Infect Dis. 2002;44:363–6.
Konate K, Mavoungou JF, Lepengue AN, Aworet-Samseny RR, Hilou A, Souza A, et al. Antibacterial activity against beta- lactamase producing Methicillin and Ampicillin-resistants Staphylococcus aureus: Fractional Inhibitory Concentration Index (FICI) determination. Ann Clin Microbiol Antimicrob. 2012;11:18.
Eliopoulos, GM, RC Moellering. Antibiotics combinations, p.432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltomore, MD. 1991.
Zhao J, Zhang Z, Xue Y, Wang G, Cheng Y, Pan Y, et al. Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I : C) promote melanoma regression. Theranostics. 2018;8:6307–21.
Fukuda H, Ohashi Y. A guideline for reporting results of statistical analysis in Japanese Journal of Clinical Oncology. Jpn J Clin Oncol. 1997;27:121–7.
Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis. 2016;45:123–34.
Lee YT, Cui CJ, Chow EW, Pue N, Lonhienne T, Wang JG, et al. Sulfonylureas have antifungal activity and are potent inhibitors of Candida albicans acetohydroxyacid synthase. J Med Chem. 2013;56:210–9.
Pan L, Jiang Y, Liu Z, Liu XH, Liu Z, Wang G, et al. Synthesis and evaluation of novel monosubstituted sulfonylurea derivatives as antituberculosis agents. Eur J Med Chem. 2012;50:18–26.
Kreisberg JF, Ong NT, Krishna A, Joseph TL, Wang J, Ong C, et al. Growth inhibition of pathogenic bacteria by sulfonylurea herbicides. Antimicrob Agents Chemother. 2013;57:1513–7.
Meng FF, Shang MH, Wei W, Yu ZW, Liu JL, Li ZM et al. Novel sulfonylurea derivatives as potential antimicrobial agents: chemical synthesis, biological evaluation, and computational study. Antibiotics (Basel). 2023;12:323.
Ovung A, Bhattacharyya J. Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions. Biophys Rev. 2021;13:259–72.
Chio LC, Bolyard LA, Nasr M, Queener SF. Identification of a class of sulfonamides highly active against dihydropteroate synthase form Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium. Antimicrob Agents Chemother. 1996;40:727–33.
McFarland MM, Zach SJ, Wang X, Potluri LP, Neville AJ, Vennerstrom JL, et al. Review of experimental compounds demonstrating anti-toxoplasma activity. Antimicrob Agents Chemother. 2016;60:7017–34.
